Abstract 728P
Background
Cervical function damage from fertility-sparing surgery reduces pregnancy success rate. Recently, immunotherapy has made significant advances in treating cervical cancer (CC). Herein, we conducted this study to evaluate the efficacy and safety of chemo + tislelizumab (TIS, a PD-L1 inhibitor) in young pts with CC who required fertility preservation.
Methods
In this trial, FIGO2018 stage IB1-IB3 or IIIC1r (localized cervical lesions) CC and having fertility needs were enrolled. Pts received 4 cycles chemo (175 mg/m2 paclitaxel + 70 mg/m2 cisplatin/AUC 5-6 carboplatin, Q3W) + TIS (200 mg, Q3W), followed by surgery-diagnostic cervical conization and sentinel lymph node (SLN) biopsy (IIIC1r stage with pelvic lymph node [PLN] systematic dissection)-upon achieving radiographic complete response (CR). After surgery, pts with pathological complete response (pCR) in all samples will undergo 2-cycle chemo + TIS, followed by TIS maintenance therapy (MT) for 1 year. If the first conization did not achieve pCR for localized cervical lesion only, a second conization was performed after 2-cycle chemo + TIS, followed by 1 year of TIS MT upon achieving pCR. Primary endpoint was pCR (SLN/PLNs + cervical conization) after surgery.
Results
Between Mar. 2022 and Apr. 2024, 8 pts (mean age 31 years) were enrolled, with 2 having stage IIIC1r disease. All 8 pts received chemo + TIS; of these, 6 pts completed 4 cycles, CR rate was 83.3%(5/6), and patients with CR received surgery. The pCR was 100% (5/5) in pts who underwent surgery, with 1 reaching a pCR after the second conization. Amenorrhea occurred in 3 of 5 pts, with 2 recovering normal menstruation post-chemo, and 1 had not returned after 3 weeks post-last chemo+TIS. During 4 cycles of chemo+TIS therapy (n=7), common TEAEs included rash (62.5%), neutropenia (62.5%), and leukopenia (62.5%), alanine aminotransferase increased (50.0%). At data cutoff (median follow-up, 9 months, range 2-25), 1 pt developed progression during MT, and 1 pt got pregnant 3 months post-MT.
Conclusions
Chemo + TIS could mediate tumor regression and eliminate micro-metastases with a tolerable safety profile, potentially preserving fertility in many pts previously considered ineligible.
Clinical trial identification
ChiCTR2300067495.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
671P - LuMIERE: A phase I/II study evaluating safety, dosimetry, and preliminary activity of [177Lu]Lu-FAP-2286 in patients with advanced solid tumors
Presenter: Jonathan McConathy
Session: Poster session 01
672P - Inference failure with synthetic arms: Empirical application to phase III oncology trials
Presenter: Alexander Decruyenaere
Session: Poster session 01
673P - Project Optimus for dose optimization: Implementation strategies for your trial from the statistician’s standpoint
Presenter: Miguel Pereira
Session: Poster session 01
674P - Patient enrollment per month (accrual) in clinical trials leading to the FDA approval of new cancer drugs
Presenter: Sebastian Albers
Session: Poster session 01
675P - Evaluation of the safety and efficacy of JSKN003 in patients with advanced HER2-positive (IHC 3+) solid tumors (excluding breast cancer)
Presenter: Lin Shen
Session: Poster session 01
678TiP - A phase I, first-in-human, dose escalation and expansion study of oral pan-RAF/MEK molecular glue NST-628 in subjects with solid tumors harboring RAS-MAPK pathway alterations
Presenter: Charlotte Lemech
Session: Poster session 01
679TiP - Cancer Research UK phase I/IIa trial of the prostaglandin E2 (PGE2) receptor 4 (EP4) antagonist HTL0039732 as monotherapy and in combination with immunotherapy in patients (pts) with advanced solid tumors
Presenter: Debashis Sarker
Session: Poster session 01
680TiP - A phase I/IIa first-in-human clinical trial evaluating MDX2001, a multi-specific antibody in patients with advanced solid tumor malignancies
Presenter: Anna Minchom
Session: Poster session 01
681TiP - A phase I/II, open label, multi-center, non-randomized dose escalation and dose expansion study of AMXI-5001 in patients with advanced malignancies
Presenter: Lee Rosen
Session: Poster session 01